Free Biopharma Daily Stock Updates - 08/04/21

$XBI $124.80 +/-0.0%

---

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

---

Covid Updates

$NVAX +18.7% Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine source

$HGEN +0.80% Lenzilumab Treatment May Provide Enhanced Likelihood of Survival Without Ventilation in Hospitalized Black and African-American COVID-19 Patients source

$SRNE +0.50% Sorrento Announces Promising Results in a Publication Detailing of Salicyn-30 and Other Salicylanilides in Reducing SARS-CoV‑2 Replication and Suppressing Induction of Inflammatory Cytokines in a Rodent Model source

Pipeline Updates

$TARS +1.5% Tarsus Pharmaceuticals, Inc. Reports Second Quarter 2021 Financial Results and Provides Business and Clinical Updates source

$SQZ -1.5% SQZ Biotechnologies Reports Second Quarter 2021 Financial Results and Recent Portfolio Updates source

$PRTK +1.7% Paratek Pharmaceuticals Announces NUZYRA® (omadacycline) Has Been Added to the CDC Plague Guidelines for the Treatment, Pre-Exposure and Postexposure Prophylaxis of Plague source

$VTVT +0.5% vTv Therapeutics Announces 2021 Second Quarter Financial Results and Provides Corporate Update source

$INMB -3.8% INmune Bio, Inc. Announces Second Quarter 2021 Results and Provides Business Update source

$OTIC +2.4% Otonomy Reports Second Quarter 2021 Financial Results and Provides Corporate Update source

$ZYME +2.0% Zymeworks Reports 2021 Second Quarter Financial Results source

$SUPN +1.0% Supernus Announces Second Quarter 2021 Financial Results source

$PTGX -0.60% Protagonist Therapeutics Reports Second Quarter 2021 Financial Results and Recent Company Progress source

$EOLS +0.60% Evolus Reports Second Quarter 2021 Results and Provides Business Update source

$ACAD -2.7% Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results source

$SRPT -2.2% Sarepta Therapeutics Announces Second Quarter 2021 Financial Results and Recent Corporate Developments source

$DVAX +1.4% Dynavax Announces Second Quarter 2021 Financial Results source

$SANA +5.7% ana Biotechnology Reports Second Quarter 2021 Financial Results and Business Updates source

$ADPT +3.8% Adaptive Biotechnologies Reports Second Quarter 2021 Financial Results source

$ALLO +0.90% Allogene Therapeutics Reports Second Quarter 2021 Financial Results source

$FATE +3.0% Fate Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Operational Progress source

$DNLI -0.50% Denali Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights source

$XNCR -1.0% Xencor Reports Second Quarter 2021 Financial Results source

$GTHX -0.60% G1 THERAPEUTICS PROVIDES SECOND QUARTER 2021 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS source

$AERI -1.6% Aerie Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update source

$PSNL +1.4% Personalis Reports Second Quarter 2021 Financial Results source

$FLXN -4.1% Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business Highlights source

$AXGN -2.8% axogen, inc. reports 2021 second quarter financial results source

$CYAD Celyad Oncology Reports First Half 2021 Financial Results and Recent Business

Highlights source

$VCEL -4.9% Vericel Reports Second Quarter 2021 Financial Results and Raises Full-Year 2021 Revenue Guidance source

$GTHX -0.60% G1 THERAPEUTICS GRANTED NEW TECHNOLOGY ADD-ON PAYMENT (NTAP) FOR COSELA™ (TRILACICLIB) BY CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) source

$BDSI -3.9% BioDelivery Sciences Reports Second Quarter 2021 Results source

$INO +1.70% INOVIO Doses First Participant in Phase 2 Trial for its DNA Vaccine Against Middle East Respiratory Syndrome (MERS), a Coronavirus Disease source

$CTMX -2.8% CytomX Therapeutics Announces Multiple Publications on Pacmilimab (CX-072), a Conditionally Activated Inhibitor of Programmed Death-Ligand 1 (PD-L1) source

$CLVS -0.80% Clovis Oncology Announces Second Quarter 2021 Operating Results source

$ALDX -1.2% Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Retinitis Pigmentosa source

$URGN -2.6% UroGen Pharma Reports Second Quarter 2021 Financial Results and Recent Corporate Developments source

$SNSE -1.3% Sensei Biotherapeutics Reports Second Quarter 2021 Results and Highlights Recent In Vivo Data from SNS-VISTA Program source

$SLGL -5.7% Sol-Gel Technologies Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments source

$HZNP +7.8% Horizon Therapeutics plc Reports Record Second-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance source

$EDIT +9.4% Editas Medicine Announces Second Quarter 2021 Results And Business Updates source

$ACIU -1.5% AC Immune Reports Second Quarter 2021 Financial Results and Provides Corporate Update source

$MORF -2.7% MORPHIC ANNOUNCES CORPORATE HIGHLIGHTS AND SECOND QUARTER 2021 FINANCIAL RESULTS source

$ONCR -3.3% ONCORUS REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS HIGHLIGHTS source

$ORTX +4.0% Orchard Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Business Updates source

$TXMD -6.7% TherapeuticsMD Announces Second Quarter 2021 Financial Results source

$SWTX +0.50% SpringWorks Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights source

$EYPT +1.8% EyePoint Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments source

$PIRS +0.30% Pieris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update source

$NRXP -8.5% MannKind Partners With NRx Pharmaceuticals To Explore A Dry Powder Formulation Of ZYESAMI™ (aviptadil) Based On The Technosphere® Platform source

$ISEE -1.1% Iveric Bio Reports Second Quarter 2021 Operational Highlights and Financial Results source

$UTHR +14% United Therapeutics Corporation Reports Second Quarter 2021 Financial Results source

---

Posted by JM